Dibucaine hydrochloride/Sodium Salicylate/Calcium Bromide

盐酸辛可卡因/水杨酸钠/溴化钙

Report date: 2026/02/02 10:55:07
NME

Base Information

Drug NameDibucaine hydrochloride/Sodium Salicylate/Calcium Bromide
Drug Alias NameNeoVitacain
ClassificationSmall molecules
Mechanisms of ActionSodium channel protein type V alpha subunit blockersSodium channel protein type X alpha subunit blockersCyclooxygenases inhibitors
TargetsSodium channel protein type V alpha subunitSodium channel protein type X alpha subunitCyclooxygenases
Therapy Area/IndicationsLow Back PainNeuralgiaMyalgia +[4] 
Global Approved IndicationsLow Back PainNeuralgiaMyalgia +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1959/08/01
Country/TerritoryJapan
CombinationsYes Dibucaine hydrochlorideSodium SalicylateCalcium Bromide
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesMitsubishi Tanabe Pharma Corp
Inactive CompaniesN/A
Active IndicationsLow Back PainNeuralgiaMyalgia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A